Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.

Abstract:

PURPOSE OF REVIEW:Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors that are changing this treatment landscape. RECENT FINDINGS:Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting. Clinical outcomes and safety profiles of these agents appear relatively comparable across separate trials; however, only pembrolizumab is supported by level I evidence from a large randomized phase III trial showing overall survival benefit over conventional cytotoxic salvage chemotherapy in the platinum-refractory setting. Pembrolizumab has the highest level of evidence in platinum-refractory aUC, whereas pembrolizumab and atezolizumab have comparable level of evidence in the frontline setting in cisplatin-ineligible patients. Ongoing research is evaluating novel agents, various rational combinations, and sequences, as well as predictive and prognostic biomarkers.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

Koshkin VS,Grivas P

doi

10.1007/s11912-018-0693-y

subject

Has Abstract

pub_date

2018-04-11 00:00:00

pages

48

issue

6

eissn

1523-3790

issn

1534-6269

pii

10.1007/s11912-018-0693-y

journal_volume

20

pub_type

杂志文章,评审
  • Early-stage Hodgkin's disease.

    abstract::Treatment of Hodgkin's disease (HD) is strictly dependent on stage. Historically, early-stage HD included the limited stages I, II, and IIIA (according to the Cotswolds modification of the Ann Arbor classsification), whereas advanced HD included stage III with B symptoms and stage IV. It was then observed that early-s...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-001-0062-z

    authors: Josting A,Diehl V

    更新日期:2001-05-01 00:00:00

  • Lung cancer screening.

    abstract::The result of a lung cancer screening program should be fewer lung cancer-specific deaths in the screened population. Studies evaluating chest imaging as a screening tool for lung cancer have not shown a reduction in lung cancer-specific mortality to date. The ability of institutions using chest imaging to meet the cr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0032-1

    authors: Mazzone PJ,Mekhail T

    更新日期:2007-07-01 00:00:00

  • Opioids and Chronic Pain: Where Is the Balance?

    abstract::Chronic opioid therapy (defined as greater than 3 months on opioids) is a common practice for those with non-cancer pain, cancer survivors with treatment-related pain, and individuals with cancer undergoing disease-modifying therapy with a survival that can be for a year or more. Recent studies have found unique long-...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-016-0558-1

    authors: Davis MP,Mehta Z

    更新日期:2016-12-01 00:00:00

  • Local delivery for gene therapy.

    abstract::Patients with head and neck cancers are excellent candidates for gene therapy. With few effective alternatives for patients with recurrent or locally metastatic disease, gene therapy offers a new approach for local control and the possibility to enhance other treatment modalities as well. Different therapeutic genes, ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-999-0024-4

    authors: Clayman GL,Dreiling L

    更新日期:1999-01-01 00:00:00

  • Recent advances in the management of gastrointestinal stromal tumors.

    abstract::Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the intestinal tract, are characterized by the expression of KIT, also known as CD117. Increasingly, primary tumors from novel sites are being described. The KIT gene is commonly mutated, causing constitutive activation of the protein and a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0068-9

    authors: von Mehren M

    更新日期:2003-07-01 00:00:00

  • Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.

    abstract:PURPOSE OF REVIEW:Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer. RECENT FINDI...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00969-w

    authors: Gentzler RD,Riley DO,Martin LW

    更新日期:2020-08-15 00:00:00

  • Prophylactic Measures During Induction for Acute Myeloid Leukemia.

    abstract:PURPOSE OF REVIEW:Improved management of infectious complications of acute myeloid leukemia (AML) has contributed substantially to the success of care over the past half century. An important approach to reducing infectious complications during the induction period of chemotherapy involves the use of prophylactic antib...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0574-9

    authors: McCarthy MW,Walsh TJ

    更新日期:2017-03-01 00:00:00

  • The changing prognosis of melanoma.

    abstract::Cutaneous melanoma is a significant and increasing clinical problem. Knowing accurately the prognosis in a given patient is critical for treatment decisions and for optimal patient education. In this article we discuss the most current information regarding prognostic factors in early-stage and advanced malignant mela...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0025-9

    authors: Buzaid AC,Anderson CM

    更新日期:2000-07-01 00:00:00

  • When and when not to use testosterone for palliation in cancer care.

    abstract::Hypogonadism is common throughout the illness trajectory of patients with cancer. About two thirds of male patients with advanced cancer have hypothalamic-pituitary-gonadal dysfunction and low testosterone levels. Chronic inflammation, comorbidities, cachexia, chemotherapy, and medications such as opioids, megestrol a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-014-0378-0

    authors: Dev R,Bruera E,Del Fabbro E

    更新日期:2014-04-01 00:00:00

  • The Management of rNPC: Salvage Surgery vs. Re-irradiation.

    abstract:PURPOSE OF REVIEW:Treatment failure, in the form of either persistence or local recurrence, occurs in 10 to 30% of nasopharyngeal carcinoma patients after initial radiotherapy (RT). Early detection of persistent or recurrent disease aids in the recognition of tumors that can be candidates for salvage nasophayngectomy o...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00949-0

    authors: Hao CY,Hao SP

    更新日期:2020-07-09 00:00:00

  • Targeted Agents in Cervical Cancer: Beyond Bevacizumab.

    abstract::Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women throughout the world. Approximately two thirds of the patients are diagnosed with locally advanced cervical cancer, showing disappointing survival rates despite correct multidisciplinary management. Metastatic disease implies a poor pr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0680-3

    authors: Marquina G,Manzano A,Casado A

    更新日期:2018-04-02 00:00:00

  • Nutrition and Aging: a Practicing Oncologist's Perspective.

    abstract::Malnutrition is common in patients with cancer and is associated with a variety of negative outcomes. These can include reduced treatment tolerance and worsened cancer prognosis. Various aspects of aging, including sensory, physical, or psychosocial changes, place older patients at a particularly high risk for malnutr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0630-5

    authors: Jain R,Dotan E

    更新日期:2017-09-07 00:00:00

  • Surgical Management of Lung Cancer: History, Evolution, and Modern Advances.

    abstract:PURPOSE OF REVIEW:Although surgery for lung cancer was not common before the early twentieth century, it has enjoyed remarkable progress since then both in type of resection and technical approach. This has been coupled with significant technological advances. Here, we will review the history and evolution of this rela...

    journal_title:Current oncology reports

    pub_type: 历史文章,杂志文章,评审

    doi:10.1007/s11912-018-0741-7

    authors: Abbas AE

    更新日期:2018-11-13 00:00:00

  • Targeting breast cancer with CDK inhibitors.

    abstract::Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential. Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy. Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0443-3

    authors: Mayer EL

    更新日期:2015-01-01 00:00:00

  • Molecular diagnosis in lymphoma.

    abstract::The evolution of our ability to diagnose and classify lymphomas in an increasingly refined manner has paralleled the development of novel technologic approaches, with contemporary practice dependent upon the harnessing of a plethora of data that include microscopic, immunophenotypic, and genetic information. Although ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-004-0063-9

    authors: Bagg A

    更新日期:2004-09-01 00:00:00

  • VEGF inhibition, hypertension, and renal toxicity.

    abstract::The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0242-z

    authors: Hayman SR,Leung N,Grande JP,Garovic VD

    更新日期:2012-08-01 00:00:00

  • Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

    abstract::The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis. Atrasentan is a novel and selective inhibitor of ET-1 and ET-A. In vitro and in vivo data show that this oral agent is capable of inh...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-006-0045-1

    authors: Thakkar SG,Choueiri TK,Garcia JA

    更新日期:2006-03-01 00:00:00

  • Current and future strategies for combined-modality therapy in pancreatic cancer.

    abstract::Treatment of pancreatic cancer remains a challenging task that often requires a multidisciplinary approach to confer optimal response and, ideally, maximize survival. A combination of locoregional approaches such as surgery and radiotherapy, along with systemic therapies for eradication of micrometastases, should be c...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0017-z

    authors: Ko AH,Tempero MA

    更新日期:2002-05-01 00:00:00

  • Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

    abstract::The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of me...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0065-2

    authors: Kounalakis N,Goydos JS

    更新日期:2005-09-01 00:00:00

  • Emerging role of proton beam radiation therapy for chordoma and chondrosarcoma of the skull base.

    abstract::Chordomas and chondrosarcomas of the skull base are rare, indolent tumors with a natural history of locally invading their surroundings. Safe, maximal resection is the mainstay of treatment, followed by adjuvant radiation therapy. Even with multimodality therapy, local recurrence remains the most common failure patter...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0052-5

    authors: Nguyen QN,Chang EL

    更新日期:2008-07-01 00:00:00

  • Prodrug/drug sensitivity gene therapy: current status.

    abstract::The prodrug strategy has its own particular real and theoretic obstacles. Clinical strategies and research efforts have tried to approach these problems. The bystander effect, whereby nontransduced cells are affected by simple proximity to those that have received the novel gene, has enabled many prodrug systems to be...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0006-z

    authors: Smythe WR

    更新日期:2000-01-01 00:00:00

  • Osteoporosis in women with breast cancer.

    abstract::Osteoporosis is a disease that causes substantial morbidity and mortality for which preventive therapy is available. Women with breast cancer are at increased risk for osteoporosis for several reasons, including premature ovarian failure as a result of treatment, direct effects of chemotherapy, and effects of the brea...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0086-7

    authors: Mincey BA

    更新日期:2003-01-01 00:00:00

  • Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

    abstract:PURPOSE OF REVIEW:Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy. Here, we review evidence regarding ALK inhibitors (ALKi): clinical activity, safety profiles, financial...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00989-6

    authors: Tabbò F,Passiglia F,Novello S

    更新日期:2021-01-02 00:00:00

  • Preoperative and adjuvant treatment of localized rectal cancer.

    abstract::Although postoperative chemoradiation has a proven role in the treatment of stage II to III localized rectal cancer, recent trials have demonstrated the role of preoperative chemoradiation. A recent randomized trial has shown that preoperative chemoradiation yields higher rates of local control and sphincter preservat...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0016-6

    authors: Das P,Crane CH

    更新日期:2006-05-01 00:00:00

  • Genetic polymorphism and cancer risk.

    abstract::Inter-individual variability in carcinogen metabolism has been attributed in part to the polymorphic expression of several phase I and II detoxification enzymes. The role of these genetic polymorphisms in cancer susceptibility has been most extensively evaluated for isozymes of cytochrome P450 (CYP1A1, CYP2D6, and CYP...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0075-z

    authors: Clapper ML

    更新日期:2000-05-01 00:00:00

  • Robotic surgery for gynaecologic cancer: an overview.

    abstract::After decades of reluctance to change surgical approaches, new technologies have created new perspectives for surgery. Initially, the laparoscopic approach was considered to be only one useful for relatively simple procedures as the design of the instruments and the limited access hampered free movements to perform co...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0270-8

    authors: Verheijen R,Zweemer R

    更新日期:2012-12-01 00:00:00

  • Communicating with Adolescents and Young Adults about Cancer-Associated Weight Loss.

    abstract:PURPOSE OF REVIEW:Over the past two decades, advances have been made in understanding the pathophysiology of cancer-associated weight loss, termed "cachexia." To date, there is no proven effective intervention to completely reverse cachexia and there are no approved drug therapies to treat it. This paper will review re...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-019-0765-7

    authors: Reid J,McKeaveney C,Martin P

    更新日期:2019-02-04 00:00:00

  • Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.

    abstract::Gastrointestinal stromal tumors (GISTs) are the most common soft tissue sarcoma, and most feature abnormalities in two genes encoding the receptor tyrosine kinases (RTKs), KIT, and PDGFRA. The RTK inhibitor imatinib revolutionized treatment in GIST; however, drug resistance remains a challenge. Constitutive autophosph...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0316-6

    authors: Patel S

    更新日期:2013-08-01 00:00:00

  • PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

    abstract::The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K) signaling pathways are commonly deregulated in cancers and promote cellular growth, proliferation, and survival. mTOR is part of two complexes, mTORC1 and mTORC2, with different biochemical structures and substrates specificity. PI3K/AKT...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0227-y

    authors: Willems L,Tamburini J,Chapuis N,Lacombe C,Mayeux P,Bouscary D

    更新日期:2012-04-01 00:00:00

  • Overview of electronic data sharing: why, how, and impact.

    abstract::Electronic data sharing is a critical, but underappreciated, requirement for modern medical informatics systems. This capability is facilitated by acquisition of structured clinical data, but optimized only if this data is stored and transmitted using standardized representations. Most electronic medical record and cl...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-012-0271-7

    authors: Jones RB,Reeves D,Martinez CS

    更新日期:2012-12-01 00:00:00